PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32235891-0	2020	Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.	Hexosamines	0-10	AKT serine/threonine kinase 1	Homo sapiens	127-130	
12135947-4	2002	Both in vivo and in vitro phosphorylation of endothelial nitric oxide synthase (eNOS) by Akt were reduced by hyperglycemia and hexosamine activation.	Hexosamines	127-137	AKT serine/threonine kinase 1	Homo sapiens	89-92	
12135947-7	2002	CONCLUSIONS: Our data show that hyperglycemia, through the hexosamine pathway, impairs activation of the IR/IRS/PI3-K/Akt pathway, resulting in deregulation of eNOS activity.	Hexosamines	59-69	AKT serine/threonine kinase 1	Homo sapiens	118-121	
15001544-0	2004	Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells.	Hexosamines	18-28	AKT serine/threonine kinase 1	Homo sapiens	161-164